Home › Lupus Nephritis › NCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Provided informed consent for the LTFU study * Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol Exclusion Criteria: * Not applicable
About the study
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).
This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
What is being tested
- KYV-101 (drug)
Sponsor: Kyverna Therapeutics · Participants: 70 · Started: Nov 24, 2025
Contact the study team
- Kyverna Therapeutics · Phone: 510-925-2484
Official record on ClinicalTrials.gov — NCT07403188
Locations in the U.S.
| Colorado | University of Colorado, Denver, Denver |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.